SFK inhibitors also proved to enhance the antitumor effects of immunotoxins against mesothelin, which is a cell-surface glycoprotein overexpressed in MM and other cancers; however, the combination of these agents has not yet been tested on MM cells [138]. Here, MSLN is linked to Miyoshi myopathy.